Celon Pharma Income Statement

Financials in millions PLN. Fiscal year is January - December.

Millions PLN. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	-	-	-	-	102.25
Revenue Growth (YoY)	-	-	-	-	-11.04%
Cost of Revenue	-	-	-	-	37.99
Gross Profit	-	-	-	-	64.26
Selling, General & Admin	-	-	-	-	62.36
Other Operating Expenses	-1.73	-16.06	14.41	8.52	-5
Total Operating Expenses	-1.73	-16.06	14.41	8.52	57.37
Operating Income	-24.87	-36.81	-10.45	-3.67	6.9
Interest Income	1.75	12.47	0.09	0.14	1.84
Interest Expense	-1.74	-9.48	-4.72	-2.06	-0.93
Total Non-Operating Income (Expense)	0.01	2.99	-4.63	-1.91	0.91
Pretax Income	-24.86	-33.82	-15.09	-5.59	7.81
Provision for Income Taxes	20.4	-4.92	-3.48	-4.67	-4.13
Net Income	-79.36	-34.45	-11.61	-0.92	11.94
Net Income to Common	-79.36	-34.45	-11.61	-0.92	11.94
Net Income Growth	-	-	-	-	-34.86%
Shares Outstanding (Basic)	53	54	47	45	45
Shares Outstanding (Diluted)	53	54	47	45	45
Shares Change (YoY)	-1.35%	15.36%	3.74%	-	-
EPS (Basic)	-1.49	-0.64	-0.25	-0.02	-0.24
EPS (Diluted)	-1.49	-0.65	-0.25	-0.02	-0.24
EPS Growth	-	-	-	-	-
Free Cash Flow	-11.08	-46.54	2.6	170.07	59.9
Free Cash Flow Growth	-	-	-98.47%	183.91%	-37.41%
Free Cash Flow Per Share	-0.21	-0.86	0.06	3.78	1.33
Dividends Per Share	-	-	0.290	0.070	0.080
Dividend Growth	-	-	314.29%	-12.50%	-66.67%
Gross Margin	-	-	-	-	62.85%
Operating Margin	-	-	-	-	6.75%
Profit Margin	-	-	-	-	11.67%
FCF Margin	-	-	-	-	58.58%
EBITDA	21.42	15.05	30.89	27.21	27.52
EBITDA Margin	-	-	-	-	26.91%
EBIT	-24.87	-36.81	-10.45	-3.67	6.9
EBIT Margin	-	-	-	-	6.75%
Effective Tax Rate	-82.06%	14.55%	23.07%	83.60%	-52.84%